Biological Activity of a Coumarin Derivative on Heart Failure Using an Ischemia/Reperfusion Injury Model

Abstract

Heart failure is a health problem worldwide. There are some drugs for it, including digoxin, spironolactone, captopril, and valsartan, but some of these drugs can produce secondary effects, such as arrhythmia, cough, hyperkalemia, hyponatremia and hypotension. The aim of this research was to evaluate the biological activity of coumarin (2H-chromen-2-one) and its derivatives (3BrAcet-C, 3–4Br-Ph-C, 4-CN-7D-C, 4-Me-7-Ph-C and 6Br-3-D-C) against ischemia/reperfusion injury as a therapeutic alternative for heart failure. In addition, the biological activity of the coumarin derivative 4-Me-7-Ph-C on left ventricular pressure (LVP) was determined in the absence or presence of ouabain and nifedipine at a dose of 1 nM using an isolated rat heart model. The results showed that i) the coumarin derivative 4-Me-7-Ph-C significantly decreased the infarct area (p+=+0.05) compared with 3BrAcet-C, 3–4Br-Ph-C, 4-CN-7D-C, and 6Br-3-D-C; and ii) 4-Me-7-Ph-C increased LVP in a dose-dependent manner, which effect was inhibited by nifedipine. These data suggest that coumarin 4-Me-7-Ph-C may act as a type-L calcium channel activator, so it could be a good agent to treat heart failure.

Key words

coumarin - heart failure - calcium channel

Publication History

Received: 30 October 2023

Accepted: 11 December 2023

Article published online:
17 January 2024

• References

• 1 Nizamitdinovich K, Alisherovna K. Quality of Life in Patients with Chronic Heart Failure, After Cardiac Resynchronization Therapy. Texas J Med Sci 2022; 14: 168-173
• 2 Osipova O, Golivets T, Khamnagadaev I. et al. Assessment of the quality of life in elderly and senile age patients with chronic heart failure. Evid Bas Care 2022; 11: 55-62
• 3 Johansson I, Joseph P, Balasubramanian K. et al. Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23000 patients from 40 countries. Circulation 2021; 43: 2129-2142
• 4 Ferreira J, Cleland J, Girerd N. et al. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur J Heart Fail 2023; 25: 108-113
• 5 Packer M, Lee WH, Yushak M. et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. New Engl J Med 1986; 315: 847-853
• 6 Szarpak L, Szwed P, Gasecka A. et al. Milrinone or dobutamine in patients with heart failure: evidence from meta-analysis. ESC Heart Fail 2022; 9: 2049
• 7 Laufer-Perl M, Sadon S, Zahler D. et al. Repetitive milrinone therapy in ambulatory advanced heart failure patients. Clin Cardiol 2022; 45: 488-494
• 8 Elsherbini H, Soliman O, Zijderhand C. et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients. Heart Fail Rev 2022; 1-13
• 9 Hu Y, Liang L, Liu S. et al. Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis. J Clin Hyp 2023; 25: 661-688
• 10 Chong L, Satya K, Kim B. et al. Milrinone dosing and a culture of caution in clinical practice. Cardiol Rev 2018; 26: 35-42
• 11 Secknus M, Marwick T. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years. J Am Coll Cardiol 1997; 29: 1234-1240
• 12 Kauffmann R, Orozco R, Venegas J. Severe hyperkalemia associated to the use of losartan and spironolactone: case report. Rev Med Chil 2005; 133: 947-952
• 13 Peng X, Damu G, Zhou H. Current developments of coumarin compounds in medicinal chemistry. Curr Pharm Design 2013; 19: 3884-3930
• 14 Ghazouani L, Khdhiri E, Elmufti A. et al. Cardioprotective effects of (E)-4-hydroxy-N′-(1-(3-oxo-3H-benzo [f] chromen-2-yl) ethylidene) benzohydrazide: a newly synthesized coumarin hydrazone against isoproterenol-induced myocardial infarction in a rat model. Canadian J Physiol Pharmacol 2019; 97: 989-998
• 15 Venugopala K, Rashmi V, Odhav B. Review on natural coumarin lead compounds for their pharmacological activity. . BioMed Res Int 2013; 963248: 1-14
• 16 Matos M, Uriarte E, Seoane N, Picos A, Gil-Longo J, Campos M. Synthesis and Vasorelaxant Activity of Nitrate-Coumarin Derivatives. ChemMedChem 2022; 17: e202200476
• 17 Hsia C, Lin K, Lee T. et al. Esculetin, a coumarin derivative, prevents thrombosis: inhibitory signaling on PLCγ2–PKC–AKT activation in human platelets. International J Mol Sci 2019; 20: 2731
• 18 Wei B, Zhou J, Xu JJ. et al. Discovery of coumarin-derived imino sulfonates as a novel class of potential cardioprotective agents. Eur J Med Chem 2019; 184: 111779
• 19 Campos-Toimil M, Orallo F, Santana L. et al. Synthesis and vasorelaxant activity of new coumarin and furocoumarin derivatives. Bioorg Med Chem Lett 2002; 12: 783-786
• 20 Jang S, Kim YJ, Lee W. et al. Scoparone from Artemisia capillaris inhibits the release of inflammatory mediators in RAW 264.7 cells upon stimulation cells by interferon-γ plus LPS. Archiv Pharm Res 2005; 28: 203-208
• 21 Yamahara J, Kobayashi G, Matsuda H. et al. The effect of scoparone, a coumarin derivative isolated from the Chinese crude drug Artemisiae capillaris flos, on the heart. Chem Pharm Bull 1989; 37: 1297-1299
• 22 Yamahara J, Kobayashi G, Matsuda H. et al. Vascular dilatory action of Artemisia capillaris bud extracts and their active constituent. J Ethnopharm 1989; 26: 129-136
• 23 Feriani A, Khdhiri E, Tir M. et al. (E)-N-(1-(7-Hydroxy-2-Oxo-2H-Chromen-3-Yl) Ethylidene) Benzohydrazide, a Novel Synthesized Coumarin, Ameliorates Isoproterenol-Induced Myocardial Infarction in Rats through Attenuating Oxidative Stress, Inflammation, and Apoptosis. Oxid Med Cell Long 2020; 432918: 1-15
• 24 Song J, Chae J, Lee K. et al. Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica 2011; 41: 895-902
• 25 Abyshev A, Gindin V, Semenov E. et al. Structure and biological properties of 2H-1-benzopyran-2-one (coumarin) derivatives. Pharm Chem J 2006; 40: 607-610
• 26 Kim J, Keum G, Chung H. et al. Synthesis and T-type calcium channel-blocking effects of aryl (1, 5-disubstituted-pyrazol-3-yl) methyl sulfonamides for neuropathic pain treatment. Eur J Med Chem 2016; 123: 665-672
• 27 Zhang Q, Xia Z, Joshi S. et al. Optimization of ADME properties for sulfonamides leading to the discovery of a T-type calcium channel blocker, ABT-639. Med Chem Lett vol 2015; 6: 641-644
• 28 Figueroa-Valverde L, Diaz-Ku E, Diaz-Cedillo F. et al. Efectos del danazol y hemisuccinato de danazol sobre la presión de perfusión y resistencia vascular. Acta Bioq Clin Lat 2010; 44: 37-46
• 29 Johnson R. Alternate Forms of the One-Way ANOVA F and Kruskal–Wallis Test Statistics. J Stat Data Sci Educ 2022; 30: 82-85
• 30 Lauro F, Francisco D, Marcela R. et al. Preparation of a steroid-oxazole-1, 2′-[1, 3] oxazete] derivative: biological and theoretical evaluation of its interaction with a kinase protein (CK2). SN Appl Sci 2019; 1: 1-12
• 31 Figueroa-Valverde L, Díaz-Cedillo F, Rosas-Nexticapa M. et al. New naphthalene-derivative as cardioprotector drug on the Ischemia/Reperfusion Injury. Biomed Pharmacol J 2005; 8: 203-212
• 32 Podbielkowska M, Waleza M, Dobrzynska K. et al. Effect of two furanocoumarins and three other coumarins on ultrastructure, ATPases and acid phosphatases in meristematic cells of Allium cepa root tips. Int J Pharm 1996; 34: 96-104
• 33 Figueroa-Valverde L, Diaz-Cedillo F, Lopez-Ramos M. et al. Changes induced by estradiol-ethylenediamine derivative on perfusion pressure and coronary resistance in isolated rat heart: L-type calcium channel. Biomed Pap 2011; 155: 27-32
• 34 Figueroa-Valverde L, Díaz-Cedillo F, López-Ramos M. et al. Actividad inotrópica inducida por el derivado carbamacepina-alquino en un modelo de corazón aislado y perfundido a flujo constante. Biomedica 2011; 31: 232-241
• 35 Schramm M, Thomas G, Towart R. et al. Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature 1983; 303: 535-537
• 36 Wada Y, Satoh K, Taira N. Cardiovascular profile of Bay K 8644, a presumed calcium channel activator, in the dog. Naunyn-Schmiedeberg’s Arch Pharmacol 1985; 328: 382-387
• 37 Ben-David J, Zipes D, Ayers G. et al. Canine left ventricular hypertrophy predisposes to ventricular tachycardia induction by phase 2 early afterdepolarizations after administration of BAY K 8644. J Am Coll Cardiol 1992; 20: 1576-1584